Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × CTLA-4 Antigen × Lymphoid × Clear all
NCT01822509 2021-06-24

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

National Cancer Institute (NCI)

Phase 1 Completed
71 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00060372 2013-03-27

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

National Cancer Institute (NCI)

Phase 1 Completed
21 enrolled
BreastCNSGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Teratoma, Testicular, Congenital Abnormalities, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Neuroblastoma, Teratoma, Testicular Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Carcinoma, Embryonal, Seminoma, Endodermal Sinus Tumor, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative